時下女生對肌膚保養的認知和期望不斷提高，不但想要五官標緻，肌膚更加要緊緻飽滿零死角！可是，隨著年紀漸長，肌膚的膠原蛋白再生能力逐漸減慢，肌膚漸趨鬆弛，失去彈性和飽滿感，無奈顯老。
想擺脫老態困擾？首選全球醫美領導廠商Allergan Aesthetics 旗下最新 HArmonyCa™美神針™，以兩大醫美成分建構出緊密細緻肌膚²，一步到位就做到即現效果和愈漸緊緻¹*，讓女生每天都感受肌膚的改變，不知不覺中擁有宛如初生般的自然緊緻！
登入 瀏覽本網站，可獲取積分換領專屬優惠
點擊查看專屬優惠
膠原再生療程新蛻變
突破過往膠原療程需要等待見效的框架，HArmonyCa™️美神針™️有別於其他只有單一主要成份的產品，以嶄新技術融合兩大醫美成份 — 透明質酸及CaHA³，一次過為肌底注入雙效優點：以透明質酸撐起凹陷流失的肌膚組織，真正做到即時拉提，同時透過CaHA成份激活纖維母細胞，促進膠原自生，持效展現緊緻效果1,2*¶。
不可不知的是，HArmonyCa™美神針™擁有科研數據證實，喚活新生膠原從療程後第一週開始4†，並於第2週起展現更顯著及更持久的拉提力，表現超越其他膠原增生療程5§！無需等待就可以還原初生緊緻肌膚，對日程緊湊而繁忙的女生而言最為吸引！
對抗老態需要「輪廓固定」
不少女生都知道，近年醫美界流行「輪廓固定」，不再停留於局部改善凹陷、鬆弛，而是整體調整內外輪廓線條，自然更顯年輕、順眼、耐看。要知道臉部「外輪廓」其實是五官的框架，沿著髮際綫、太陽穴、顴骨、下顎線至下巴從臉部外型拉提支撐，就能改善漸漸出現鬆垮的皮膚和輪廓，凸顯精緻立體感。
HArmonyCa™️美神針™️的一大優點是配合獨特的「C-Shape拉提」療程手法，定點加強支撐內外輪廓，拉提出自然弧度，讓肌膚更顯緊緻貼服¹*，不怕因局部過度改善而出現不自然的反效果，美得自然有氣質！
誰能夠抗拒緊緻有提拉感的肌膚呢？
與 BOTOX®保妥適®及Juvéderm®喬雅登®同屬 Allergan Aesthetics 旗下醫美品牌，HArmonyCa™️美神針™️讓女生擁有即時可見拉提緊緻，同時於肌底持效激活膠原蛋白自生¹*，打造讓91.6%用家見證改善效果6‡，迎來緊緻明亮的面部輪廓。
療程前必要認清 HArmonyCa™ 美神針™ 產品外盒上貼有防偽鐳射標籤，確保療程放心又可靠。
立即向 HArmonyCa™美神針™原廠供應的醫療中心查詢療程詳細內容及價格：http://bit.ly/4619sJ4
*Results from a prospective and non-randomised interventional study where HArmonyCa™ was injected in the preauricular region of 15 women. The primary endpoint were the volumetric changes at Day 180. econdary endpoints included changes in facial tension vectors, the treatment efficacy, time to filler tissue integration and safety profile.¹ ¶Results from a single-centre, prospective, quasi-experimental controlled study where HArmonyCa™ was injected in different areas of the face of 15 participants. Ultrasound analysis (high-frequency ultrasound LogicE device [GE Healthcare] was used to assess dermal thickness at baseline (mean: 1.47 ± 0.08 mm) and at 30, 90, and 120 days (mean: 1.68 ± 0.08 mm) following the intervention. The variations analysed were significant (p<0.001) except between baseline and at 30 days.2 †Results from a pre-clinical animal study of HArmonyCa™ with results demonstrated over 8 weeks.4 §Results from a pre-clinical animal study of HArmonyCa™ with results demonstrated over 12 weeks.5 ‡A post marketing clinical follow up of safety and performance of HArmonyCa™ (N=162). Performance evaluation using the Global Aesthetic Improvement Scale.6
References: 1. Urdiales-Gálvez F et al., J Cosmet Dermatol. 2023;00:1–12; 2. Bravo B et al. Plast Reconstr Surg Glob Open. 2023;15(11):1–10; 3. HArmonyCa™ IFU. 73960EU10. M049 V01. Revision December 2021; 4. Allergan Aesthetics. Data on File. HArmonyCa™ Lidocaine. INT-HAR-2150040. Collagen stimulation. July 2021. REF-84450; 5. Allergan Aesthetics. Data on File. HArmonyCa™ Lidocaine INT-HAR-2150036. Lift capacity. July 2021. REF-84448; 6. Allergan Aesthetics. Data on File. HArmonyCa™ Lidocaine. Clinical Study Report. July 2022.
HArmonyCa™ (calcium hydroxyapatite, hyaluronic acid gel with lidocaine). BOTOX® (Botulinum Toxin Type A) Drug Registration Number: HK-41906. Juvéderm® (Hyaluronic Acid Gel with Lidocaine) product series includes VOLUX™ (HKMD-190341), VOLUMA® (HKMD-100411), VOLIFT® (HKMD-130324), VOLBELLA® (HKMD-210451) and VOLITE™ (HKMD-180040). All adverse events should be reported to drugsafety.pv@abbvie.com. © 2024 Allergan Aesthetics. All rights reserved. HK-HAR-240014 | 23/APR/24
資料由客戶提供